智通财经APP获悉，贝康医疗-B(02170)尾盘涨近6%，截至发稿，涨4.83%，报3.91港元，成交额438.54万港元。
消息面上，贝康医疗宣布，Gems培养液（胚胎处理液VitBase）正式获得国家药品监督管理局（NMPA）签发的注册证，这不仅是中国辅助生殖领域的一项里程碑事件，更标志着国产高端培养液正式迈入国际领先阵营，彻底打破三十余年来进口品牌垄断的局面。
据悉，VitBase隶属于贝康旗下国际品牌BMX开发的明星产品GEMS系列。贝康Gems培养液是中国胚胎师青睐的培养液之一，至今已有30年历史。目前11款获欧盟CE认证，8款通过美国FDA批准，11款符合澳大利亚TGA标准，可覆盖辅助生殖全流程。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.